The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera.
they began a phase three trial testing whether the treatment can prevent the spread of coronavirus in residents and staff at nursing homes.
The second trial, in a late stage, will look patients who have been hospitalized with mild to moderate Covid-19 with fewer than 13 days of symptoms and aims to enroll a total of 1,000 people. Researchers in the phase three trial want to see whether the antibody treatment can promote a sustained recovery for two weeks at home, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on a conference call with reporters.
The trials are part of the NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines program, a partnership with drugmakers and other U.S. agencies to coordinate drug and vaccine research.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly launches late-stage antibody treatment trial to be tested in US nursing homesEli Lilly is launching a late-stage study of its monoclonal antibody technology, and has employed a mobile treatment van to deliver this therapy to nursing homes.
Weiterlesen »
Eli Lilly Studies Experimental Covid-19 Drug in Nursing HomesThe late-stage trial is exploring whether Eli Lilly’s antibody drug can help reduce infections in senior facilities with a diagnosed case of the new coronavirus.
Weiterlesen »
Eli Lilly starts late-stage study of coronavirus drug in nursing homesU.S. drugmaker Eli Lilly said on Monday it is beginning a late-stage trial to study whether one of its experimental Covid-19 antibody treatments can prevent the virus' spread in residents and staff in U.S. nursing homes.
Weiterlesen »
Eli Lilly starts late-stage study of COVID-19 drug in nursing homesU.S. drugmaker Eli Lilly & Co is beginning a late-stage trial to study whether one of its experimental COVID-19 antibody treatments can prevent the spread of the virus in residents and staff at U.S. nursing homes, it said on Monday.
Weiterlesen »
Lilly begins nursing home trials with antibody drug for COVID-19 preventionUS drugmaker Eli Lilly & Co. says it is beginning a late-stage trial to study whether one of its experimental COVID-19 antibody treatments can prevent the virus' spread in residents and staff in nursing homes.
Weiterlesen »
Eli Lilly Studies Experimental Covid-19 Drug in Nursing HomesThe late-stage trial is exploring whether Eli Lilly’s antibody drug can help reduce infections in senior facilities with a diagnosed case of the new coronavirus.
Weiterlesen »